Senesco Technologies, Inc. Release: Combining SNS01-T with Bortezomib Significantly Increases Its Effectiveness in Model of Multiple Myeloma

Published: Sep 10, 2012

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) announced today that the combination of bortezomib (the active component of VELCADE® marketed by Millennium, The Takeda Oncology Company) and SNS01-T, the subject of Senesco’s on-going multiple myeloma clinical study, performs significantly better than either treatment alone in mouse xenograft models.

Back to news